Total Payments
$8,260
2024 Payments
$25.00
Companies
32
Transactions
463
Medicare Patients
15,514
Medicare Billing
$3.2M
Payment Breakdown by Category
Food & Beverage$8,017 (97.0%)
Education$243.77 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,017 | 425 | 97.0% |
| Education | $243.77 | 38 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,466 | 54 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $934.37 | 52 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $763.60 | 39 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $749.70 | 53 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $684.86 | 61 | $0 (2020) |
| PFIZER INC. | $659.57 | 64 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $625.66 | 39 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $525.14 | 33 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $298.62 | 19 | $0 (2019) |
| Ablacon, Inc. | $241.24 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25.00 | 1 | E.R. Squibb & Sons, L.L.C. ($25.00) |
| 2023 | $241.24 | 1 | Ablacon, Inc. ($241.24) |
| 2021 | $11.72 | 1 | Amgen Inc. ($11.72) |
| 2020 | $731.11 | 29 | Medicure Pharma Inc. ($227.81) |
| 2019 | $2,612 | 156 | Amgen Inc. ($586.95) |
| 2018 | $2,093 | 125 | Amgen Inc. ($466.37) |
| 2017 | $2,546 | 150 | Amgen Inc. ($381.79) |
All Payment Transactions
463 individual payment records from CMS Open Payments — Page 19 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/07/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $1.49 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/03/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/27/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/27/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/27/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Education | In-kind items and services | $6.97 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/27/2017 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $6.71 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/26/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $2.68 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/25/2017 | Aralez Pharmaceuticals US Inc. | YOSPRALA (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/21/2017 | Actelion Pharmaceuticals US, Inc. | OPSUMIT MACITENTAN (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: CARDIOVASCULAR DISORDERS | ||||||
| 01/17/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.12 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/13/2017 | Bayer HealthCare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Cardio-pulmonary | ||||||
| 01/12/2017 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $18.39 | General |
| Category: Cardiovascular | ||||||
| 01/09/2017 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 4,030 | 5,706 | $3.4M | $822,294 |
| 2022 | 32 | 3,987 | 5,730 | $3.1M | $784,403 |
| 2021 | 34 | 3,893 | 5,745 | $3.2M | $839,534 |
| 2020 | 30 | 3,604 | 5,765 | $2.8M | $709,301 |
Total Patients
15,514
Total Services
22,946
Medicare Billing
$3.2M
Procedure Codes
126
All Medicare Procedures & Services
126 procedure records from CMS Medicare Utilization — Page 3 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 18 | 18 | $6,678 | $1,727 | 25.9% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2022 | 67 | 69 | $6,624 | $1,655 | 25.0% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2022 | 103 | 107 | $6,313 | $1,499 | 23.7% |
| 93279 | Programming of single lead pacemaker system | Office | 2022 | 12 | 23 | $5,727 | $1,472 | 25.7% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2022 | 31 | 51 | $6,222 | $1,180 | 19.0% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Office | 2022 | 15 | 16 | $6,512 | $1,167 | 17.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2022 | 27 | 46 | $6,624 | $1,146 | 17.3% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2022 | 67 | 69 | $4,140 | $999.03 | 24.1% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2022 | 12 | 37 | $3,774 | $875.30 | 23.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 12 | 12 | $2,844 | $761.74 | 26.8% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2022 | 28 | 29 | $6,003 | $319.19 | 5.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 735 | 1,405 | $647,705 | $226,061 | 34.9% |
| 78492 | Multiple nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2021 | 121 | 123 | $1.0M | $194,122 | 18.6% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 561 | 607 | $495,529 | $115,810 | 23.4% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2021 | 121 | 246 | $195,570 | $102,710 | 52.5% |
| 93351 | Ultrasound examination and continuous monitoring of the heart performed during rest, exercise, and/or drug-induced stress with interpretation and report | Office | 2021 | 117 | 119 | $119,595 | $26,090 | 21.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 231 | 262 | $89,866 | $26,037 | 29.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2021 | 123 | 500 | $72,000 | $24,000 | 33.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 86 | 86 | $55,900 | $17,070 | 30.5% |
| 93280 | Evaluation, testing, and programming adjustment of permanent dual lead pacemaker system with physician analysis, review, and report | Office | 2021 | 64 | 164 | $43,460 | $12,401 | 28.5% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 623 | 876 | $67,452 | $11,101 | 16.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 58 | 118 | $41,064 | $11,006 | 26.8% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Office | 2021 | 132 | 138 | $56,166 | $9,720 | 17.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 44 | 48 | $32,160 | $8,540 | 26.6% |
| 93015 | Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report | Office | 2021 | 108 | 109 | $36,624 | $7,456 | 20.4% |
About Dr. Bruce Benedick, M.D
Dr. Bruce Benedick, M.D is a Interventional Cardiology healthcare provider based in E Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346274602.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Benedick, M.D has received a total of $8,260 in payments from pharmaceutical and medical device companies, with $25.00 received in 2024. These payments were reported across 463 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($8,017).
As a Medicare-enrolled provider, Benedick has provided services to 15,514 Medicare beneficiaries, totaling 22,946 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 126 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Cardiology
- Other Specialties Nuclear Cardiology, Cardiovascular Disease
- Location E Palo Alto, CA
- Active Since 07/10/2006
- Last Updated 05/28/2020
- Taxonomy Code 207RI0011X
- Entity Type Individual
- NPI Number 1346274602
Products in Payments
- ELIQUIS (Drug) $1,451
- Corlanor (Drug) $848.72
- XARELTO (Drug) $732.75
- ENTRESTO (Drug) $625.66
- Repatha (Biological) $617.42
- PRALUENT (Drug) $580.21
- BRILINTA (Drug) $525.14
- PRADAXA (Drug) $508.21
- Heart Failure Device. (Device) $227.81
- MULTAQ (Drug) $183.39
- JARDIANCE (Drug) $176.65
- PRALUENT (Biological) $160.72
- PRALUENT ALIROCUMAB INJECTION (Biological) $137.90
- VYNDAQEL (Drug) $122.12
- KENGREAL (Drug) $117.44
- Circulatory Support (Device) $106.27
- WATCHMAN (Device) $99.45
- LifeVest (Device) $74.09
- Veltassa (Drug) $58.45
- Vascepa (Drug) $56.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.